• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Praluent (alirocumab) - Articles and news items

nice

NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…

evolocumab

NICE recommends alirocumab and evolocumab in draft guidance

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia…

apheresis

Positive results for Praluent in patients undergoing LDL apheresis therapy

Industry news / 23 March 2016 / Victoria White

Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo….

heart uk

Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use

Industry news / 12 February 2016 / Victoria White

Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs…

alirocumab

NICE says ‘no’ to alirocumab in draft guidance

Industry news / 8 February 2016 / Victoria White

NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes…

praluent

EC approves LDL cholesterol treatment Praluent

Industry news / 28 September 2015 / Victoria White

Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy…

praluent

FDA approves Praluent for the treatment of high LDL cholesterol

Industry news / 26 August 2015 / Victoria White

The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection – the first and only PCSK9 inhibitor approved in the US…

cordis

Thomson Reuters names most promising drugs of 2015

Industry news / 24 March 2015 / Victoria White

The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report…

six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol

Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol

Industry news / 19 November 2014 / Sanofi / Regeneron Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its ability to lower LDL-C…

GlobalData

Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst

Industry news / 12 November 2014 / GlobalData

Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData…

Sanofi

Sanofi and Regeneron present detailed positive results from four pivotal Alirocumab trials at ESC Congress 2014

Industry news / 2 September 2014 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia…

GlobalData

New blockbuster drugs to more than triple acute coronary syndrome treatment market value by 2023

Industry news / 29 July 2014 / GlobalData

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +